|
Title
|
|
|
|
Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy
| |
|
Author
|
|
|
|
| |
|
Abstract
|
|
|
|
| Owing to their professional antigen-presenting capacity and unique potential to induce tumor antigen-specific T cell immunity, dendritic cells (DCs) have attracted much interest over the past decades for therapeutic vaccination against cancer. Clinical trials have shown that the use of tumor antigen-loaded DCs in cancer patients is safe and that it has the potential to induce anti-tumor immunity which, in some cases, culminates in striking clinical responses. Unfortunately, in a considerable number of patients, DC vaccination is unable to mount effective anti-tumor immune responses and, if it does so, the resultant immunity is often insufficient to translate into tangible clinical benefit. This underscores the necessity to re-design and optimize the current procedures for DC vaccine manufacturing. A new generation of DC vaccines with improved potency has now become available for clinical use as a result of extensive pre-clinical research. One of the promising next-generation DC vaccine candidates are interleukin (IL)-15-differentiated DCs. In this commentary, we will compile the research data that have been obtained by our group and other groups with these so-called IL-15 DCs and summarize the evidence supporting the implementation of IL-15 DCs in DC-based cancer vaccination regimens. |
| |
|
Language
|
|
|
|
English
| |
|
Source (journal)
|
|
|
|
Human vaccines & immunotherapeutics. - Philadelphia, Pa, 2012, currens
| |
|
Publication
|
|
|
|
Philadelphia, Pa
:
2013
| |
|
ISSN
|
|
|
|
2164-5515
[print]
2164-554X
[online]
| |
|
DOI
|
|
|
|
10.4161/HV.25373
| |
|
Volume/pages
|
|
|
|
9
:9
(2013)
, p. 1956-1961
| |
|
ISI
|
|
|
|
000330295900027
| |
|
Full text (Publisher's DOI)
|
|
|
|
| |
|